Search
for
Sort by
Research 691–720 of 1000+
- Cure of alopecia areata after eradication of Helicobacter pylori: a new association?
- Exploring the relationship between anastasis and mitochondrial ROS-mediated ferroptosis in metastatic chemoresistant cancers: a call for investigation
- Hodgkin′s lymphoma presenting as alopecia
- Paradise Nut Paradox: Alopecia Due to Selenosis from a Nutritional Therapy
- Effect of Sun exposure-induced ferroptosis mechanisms on pathology and potential biological processes of primary melanoma by microarray data analysis
- Chemical and Bioactive Properties of Red Rice with Potential Pharmaceutical Use
- Crystallin Fusion Proteins Improve the Thermal Properties of Hair
- Skin Microbiome, Metabolome and Skin Phenome, from the Perspectives of Skin as an Ecosystem
- Structure, Function and Application of <i>Tremella Fuciformis</i> Polysaccharide: A Review
- Alopecia and Semaglutide: Connecting the Dots for Patient Safety
- Mineral, trace element, and toxic metal concentration in hair from dogs with idiopathic epilepsy compared to healthy controls
- Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial
- The Therapeutic Response of Platelet Rich Plasma (PRP) for Androgenetic Alopecia Showed No Correlation with Growth Factors and Platelet Number
- Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
- Intermittent chronic telogen effluvium with an unusual dermoscopic finding following COVID ‐19
- Phenotypic effect of growth media on <i>Arabidopsis thaliana</i> root hair growth
- Abstracts from the 4th Annual Student Medical Summit
- Potential Treatment of Steroid‐Resistant Alopecia Areata Using Allogeneic Exosomes Derived From Adipose Tissue Mesenchymal Stromal Cells: A Case Report
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ANALYSIS OF TRIGGER FACTORS FOR ACUTE TELOGEN HAIR LOSS IN WOMEN OF REPRODUCTIVE AGE
- Evaluation of Efficacy of Platelet rich Plasma on Androgenetic Alopecia: A Multimodal Assessment Using Trichoscopy, Histopathology, and CD34 Immunohistochemical Assay
- Preclinical and Clinical Efficacy of a Green Tea, Bamboo, and Selenium Supplement for the Management of Acute Telogen Effluvium in Women
- COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
- Synthesis of a new amino acid derivative with long‐lasting hair shape control effects and elucidation of its mechanisms
- KeraGLO® Hydrolyzed Keratin: A Healthy Aging Supplement, Improved Skin and Hair in a Placebo Controlled Trial
- Causal effects of genetically determined metabolites on androgenetic alopecia: A two‐sample Mendelian randomization analysis
- Cellular therapeutics and immunotherapies in wound healing – on the pulse of time?
- Transcriptome analysis of frontal fibrosis alopecia revealed involvement of immune cells and ferroptosis
- A Multidisciplinary Lifestyle Intervention for Women with Polycystic Ovary Syndrome: The Role of a Pulse-Based Diet and Aerobic Exercise on Reproductive, Cardio-Metabolic, and Quality of Life Outcomes